

Immunicum reports continued promising survival data for INTUVAX-treated renal cancer patients

GOTHENBURG, December 3, 2014. Immunicum AB (publ) today announced continued promising data from a phase I/II trial in patients with metastatic renal cell carcinoma. The median survival in the subgroup of five individuals who were initially classified as high-risk patients now stands at 19.8 months, compared with an expected median survival of nine months following current standard therapy. Seven of the eleven evaluable patients in the study, of which two belong to the original group of five high-risk patients, are still alive.

In total, six of eleven patients have now received add-on therapy with tyrosine kinase inhibitors (TKI) due to tumor growth. Three of these patients (all with massive infiltration of CD8+ T cells in the removed kidney tumor) have noted a pronounced and prolonged regression of metastases.

Continued monitoring is necessary to clarify the effect on survival in patients with a slightly less aggressive disease (intermediate mRCC). Five of the six patients in this subgroup are still alive, three of which have achieved a survival time of more than two years.

– It is gratifying that the median survival in the INTUVAX-treated renal cancer patients continues to increase. We are now preparing a comprehensive phase II study in the same indication and expect this to be able to start in early 2015, says Immunicum's CEO, Jamal El-Mosleh.

The purpose of the phase I/II study was to document the adverse event profile and immunological effects, and to follow the survival of patients with metastatic renal cell carcinoma after treatment with two INTUVAX injections.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

Alex Karlsson-Parra, CSO, Immunicum
Phone: +46 (0) 705 16 75 79
alex.karlsson-parra@immunicum.com

The company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se

About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the company's most advanced project - INTUVAX[®] against renal cancer - is expected to start in early 2015. The project portfolio contains three further projects against various tumor diseases, including liver cancer.

www.immunicum.com